Unicycive slides as FDA delay, dilution weigh premarket
Unicycive Therapeutics, Inc. dropped in premarket trading Tuesday after the FDA denied approval for its kidney-disease drug again. Investors are now weighing how much of the stock’s value rests on that asset, net of cash.
